Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ImCyse

ImCyse
2010 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Grant LATEST DEAL TYPE
$5.16M LATEST DEAL AMOUNT
9 INVESTORS
Description

Manufacturer of therapeutic vaccines designed to offer tre3atment of multiple sclerosis and diabetes. The company's vaccines allow destroying locally the immune cells involved in the destruction of the diseased organ for the generation of a new type of T-cell called cytolytic CD4 and prevent the immunogenic responses that weaken the efficiency of chronic therapies, enabling physicians to treat and prevent severe chronic diseases caused by disruptions of the immune system.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Primary Office
  • GIGA B34
  • Avene de l'Hôpital 1,Sart Tilman
  • 4000 Liege
  • Belgium
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ImCyse’s full profile, request a free trial.

ImCyse Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 18-Jun-2019 $5.16M 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 18-Jun-2019 000.00 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC 30-Nov-2017 00.000 00.000 000.00 Completed Clinical Trials - Phase 2
4. Early Stage VC 27-Aug-2014 00.000 00.000 000.00 Completed Startup
3. Early Stage VC 01-Nov-2012 00.000 00.000 000.00 Completed Startup
2. Early Stage VC 09-Feb-2011 $270K $270K 00000 Completed Startup
1. Accelerator/Incubator 01-Jan-2011 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

ImCyse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Class E 00,000 000.00 000.00 00 000.00 0.000
Class C 000 000.00 000.00 00 000.00 0.000
Class B 000 000.00 000.00 00 000.00 0.000
Class D 00,000 00.00 00.00 00 00.00 0.000
Class C 0,000 00.00 00.00 00 00.00 0.000
Class E 0,000 000.00 000.00 00 000.00 0.000
Class B 0,000 000.00 000.00 00 000.00 0.000
Class E 00,000 000.00 000.00 00 000.00 0.000
Class C 469 $24.06 $24.06 1x $24.06 0.05%
Class A 5,861 $24.06 $24.06 1x $24.06 0.61%
To view this company’s complete Cap Table, request access »

ImCyse Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Biogenosis Corporation Minority 000 0000 000000 0
Epimède Venture Capital Minority 000 0000 000000 0
Federal Holding and Investment Company Holding Company Minority 000 0000 000000 0
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
Société Régionale d'Investissement de Wallonie Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

ImCyse Executive Team (7)

Name Title Board
Seat
Contact
Info
Pierre Vandepapelière Ph.D Chief Executive Officer, Board Member & CMO
Luc Elst Ph.D Co-Founder & Director, Research & Development
Jean-marie Saint-Remy Ph.D Co-Founder
Vincent Carlier Co-Founder
Jean Smal Senior Advisor, Development and Manufacturing

1 Former Executive

You’re viewing 5 of 7 executives. Get the full list »

ImCyse Board Members (5)

Name Representing Role Since Contact
Info
Colin Dalton Self Board Member 000 0000
Jean Foidart ImCyse Board Member and Scientific Advisor 000 0000
Joseph Martial ImCyse Board Member 000 0000
Marc Foidart Noshaq Chairman 000 0000
Stijn Van Rompay Self Board Member 000 0000